Clinical Trials on Tobacco, Smoking in Japan

Total 19 results

Philip Morris Products S.A.

Unknown

Japanese Post-Market Cohort Study

Smoking | Tobacco Product

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile of the CHTP 1.1 M

Smoking

Japan
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

Japan
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers

Smoking | Healthy

Japan
Philip Morris Products S.A.

Completed

A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation (RIBESC)

Cigarette Smoking

United States, Poland, Germany, Japan, United Kingdom
Philip Morris Products S.A.

Completed

Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking

Smoking | Inflammation | Oxidative Stress | Smoking Abstinence

Japan, Germany, Czechia, Greece
Pfizer

Completed

A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking

Smoking

Japan
Ibtihal Altalhi

Unknown

Effectiveness of Mobile Phone-Based Intervention to Prevent Smoking Relapse Among Recent Smoking Quitters

Smoking Cessation

Saudi Arabia
Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

Smoking Cessation

Japan
Philip Morris Products S.A.

Completed

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

Smoking | Abdominal Aortic Aneurysm | IQOS Use

Japan
Nagano Children's Hospital

Recruiting

Effects of Parents Included in Medical Round of Neonatal Intensive Care Unit

Decision Making | Family Centered Care

Japan
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Smoking Cessation

United States, Taiwan, Australia, Germany, Egypt, United Kingdom, Canada, Czech Republic, Mexico, Japan
Association for the Japanese Academy of Maxillofacial...

Unknown

Tobacco Cessation Intervention Study for Oral Diseases (TISOD)

Smoking Cessation | Periodontal Diseases | Mouth Diseases | Keratosis | Leukoplakia | Implant | Lichen Planus

Japan
Philip Morris Products S.A.

Recruiting

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Smoking | Tobacco Use | COPD

United States, Bulgaria, Czechia, Germany, Japan, Romania, Slovakia, United Kingdom
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Periodontal Diseases | Gingival Diseases | Chronic Periodontitis | Smoking, Cigarette | Periodontal Pocket | Tooth Mobility

Japan
Bispebjerg Hospital
World Health Organization; International Network of Health Promoting Hospitals... and other collaborators

Completed

WHO-HPH Recognition Project on Fast-Track Implementation of Clinical Health Promotion (RP)

Smoking | Obesity | Malnutrition | Excessive Drinking | Lack of Physical Activity

Canada, Croatia, Czechia, Denmark, Estonia, Indonesia, Japan, Malaysia, Slovenia, Taiwan, Thailand

Clinical Trials on Tobacco, Smoking in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations